When limited RNA input, antibody variability, or broad enrichment peaks restrict your m6A study, m6A-Atlas provides a low-input m6A sequencing service for transcriptome-wide mapping at single-nucleotide resolution. It identifies high-confidence candidate m6A sites and connects modification-associated changes with transcript expression across experimental conditions.
Key Highlights of Our m6A-Atlas Service:
Low-Input Compatibility: Qualified projects can start from as little as 10 ng total RNA, preserving precious material for broader experimental designs.
Antibody-Free Detection: Reduced dependence on antibody specificity and lot-to-lot enrichment performance supports clearer cross-group comparisons.
Single-Nucleotide Resolution: Candidate sites are localized beyond broad enriched regions, enabling transcript-region and gene-level interpretation.
Integrated Analysis: Modification-associated signals are evaluated together with gene and transcript expression to prioritize mechanistic candidates.
m6A-Atlas is an antibody-free, low-input m6A sequencing service that maps high-confidence candidate sites across the transcriptome at single-nucleotide resolution. It is designed for discovery projects that need more precise site localization than broad enrichment peaks and for comparative studies that must connect modification-associated changes with RNA expression.
Qualified projects can start from as little as 10 ng total RNA, while 50 ng or more is recommended when available. Lower sample consumption makes limited cell populations and precious experimental material accessible to transcriptome-wide m6A research, although minimum-input projects require pre-assessment of RNA quality and study complexity.
Candidate sites are evaluated through read support, signal thresholds, biological replicate consistency, matched controls, and sequence-context evidence. This multi-layer framework narrows the result set to reproducible candidates that can be prioritized for downstream validation.
Figure 1. Multi-layer evidence used to prioritize reproducible candidate m6A sites without disclosing the underlying assay implementation.
Advantages
Why Use m6A-Atlas for Low-Input m6A Sequencing?
Each technical feature is tied to a practical research decision: preserving limited material, reducing enrichment-related variability, resolving candidate sites more precisely, and connecting m6A changes with transcript abundance.
Low Input Without Losing the Research Question: Qualified projects can start from 10 ng total RNA. This lowers sample consumption so scarce material can support transcriptome-wide discovery rather than only a small targeted panel.
Antibody-Free Detection: The workflow avoids antibody enrichment. This reduces dependence on reagent specificity, cross-reactivity, and lot variation when samples are compared across groups or batches.
Single-Nucleotide-Resolution Mapping: Candidate signals are assigned to individual nucleotide positions instead of broad regions. Researchers can therefore connect results with transcript features and prioritize defined sites for validation.
Modification–Expression Integration: Candidate-site changes are analyzed alongside gene and transcript expression. This distinguishes modification-only, expression-only, concordant, and opposing patterns.
Multi-Layer Confidence Filtering: Coverage, signal strength, replicate support, controls, and sequence context are evaluated together. This reduces unsupported calls and produces a more interpretable validation list.
Traceable Bioinformatics: Filtering records, analysis parameters, and project logs are retained. This supports result review, manuscript preparation, and future reanalysis.
Workflow
From Limited RNA to an Interpretable m6A Atlas
The workflow protects limited material while documenting each decision from study design through site filtering and integrated reporting. Quality-control checkpoints are placed before irreversible sample use and before group-level interpretation.
Figure 2. End-to-end project workflow with quality-control checkpoints from study design to final reporting.
1. Study Design
Define the biological question, groups, species, comparisons, and controls.
QC: Confirm replicate structure and matched controls.
2. Sample QC
Evaluate RNA quantity, purity, integrity, contamination, and group consistency.
QC: Approve feasibility before limited material is consumed.
3. Library Preparation
Prepare low-input libraries that retain transcriptome information and m6A-associated signals.
QC: Assess library yield and size distribution.
4. Sequencing
Select configuration according to species, transcriptome complexity, and study goals.
QC: Review base quality, read yield, and sample balance.
5. Site Analysis
Align reads and filter candidate sites by coverage, signal, replicates, controls, and context.
QC: Document retained and excluded candidates.
6. Integrated Report
Annotate sites, compare groups, integrate expression, and interpret functional patterns.
These planning ranges help determine project feasibility. Final requirements depend on RNA quality, species, transcriptome complexity, and the intended comparison.
Sample Type
Recommended Input
Minimum Input
Quality Guidance
Notes
Total RNA
≥50 ng
10 ng for qualified samples
Intact, high-purity, RNase-free RNA
Feasibility depends on RNA quality and transcript abundance
Cultured cells
Sufficient to obtain ≥50 ng total RNA
Project-dependent
High viability and contamination-free
Cell number varies with cell size, state, and RNA yield
Fresh or frozen tissue
Project-dependent
Project-dependent
Rapid freezing and proper storage recommended
RNA extraction and feasibility review may be required
Plant RNA or tissue
≥50 ng RNA recommended
Project-dependent
Minimal polysaccharide and polyphenol contamination
Species and genome annotation should be reviewed
Microbial RNA
Project-dependent
Project-dependent
High-purity RNA with controlled degradation
RNA composition and transcriptome complexity require pre-assessment
At least three biological replicates per condition are recommended for comparative studies. Replication estimates within-group variation, which improves confidence when identifying condition-associated changes. Heterogeneous tissues or subtle expected effects may require additional replicates.
Bioinformatics Analysis Built Around Site Confidence
The analysis workflow records how candidate sites were identified, which filters were applied, how biological replicates performed, and how modification-associated changes relate to expression and biological function.
Sequencing Data Quality Control
Raw read assessment, adapter removal, low-quality filtering, reference alignment, coverage evaluation, sample correlation, and replicate consistency identify technical outliers before biological interpretation.
High-Confidence Candidate Sites
Candidate detection, coverage filtering, signal thresholds, replicate support, matched controls, and sequence context reduce unsupported calls and prioritize actionable sites.
Transcriptome Annotation
Coordinates are assigned to genes, transcripts, 5′ UTRs, coding regions, stop-codon-proximal regions, and 3′ UTRs, linking sites with RNA fate and regulatory context.
Gene and transcript expression, differential expression, four-quadrant classification, GO, KEGG, and network analysis separate modification effects from abundance effects.
Reproducible Analysis Records
Workflow parameters, filtering records, and analysis logs maintain consistent metric definitions across batches and make later review more efficient.
Demo
Representative m6A-Atlas Results
Representative outputs are selected to answer defined research questions rather than only demonstrate technical quality. Public or internally approved datasets should be labeled clearly on the live page.
Figure 3. Illustrative analysis outputs. Public or internally approved datasets should be clearly labeled when displayed on the live page.
Transcriptome-Wide Site Distribution
Metagene and transcript-region plots show candidate-site distribution across 5′ UTRs, coding regions, stop-codon-proximal regions, and 3′ UTRs.
Sequence-Context and Motif Analysis
Motif and sequence-context summaries provide a biological plausibility check beyond read support.
Differential Candidate Sites
Scatter plots, volcano plots, and shared-versus-specific summaries identify sites that differ between conditions and support validation ranking.
m6A–Expression Integration
Four-quadrant plots and heatmaps classify genes by modification-associated and expression change.
Gene-Level Browser Views
Gene tracks support detailed inspection, targeted validation, and manuscript figure preparation.
Sample Correlation
Correlation heatmaps show whether biological replicates cluster by condition and support differential analysis.
Deliverables
Data Deliverables
Each project includes reusable data files and an interpretation-ready report. Deliverables are linked to defined analysis stages so results can be reviewed independently or extended through custom downstream analysis.
Deliverable
Contents
Research Value
Raw and clean sequencing data
FASTQ files and processed read files
Supports independent quality review and reanalysis
Alignment files
BAM files and index files
Enables gene-level inspection and custom visualization
Candidate-site table
BED or TSV coordinates, gene and transcript IDs, region annotation, relative signal, fold change, replicate support, and confidence indicators
Provides an actionable list for prioritization and validation
Expression matrices
Gene and transcript abundance and differential expression tables
Separates modification-associated changes from abundance effects
Visualization package
Site summaries, metagene plots, region composition, correlation heatmaps, differential figures, and browser tracks
Supports interpretation, presentations, and manuscripts
Functional analysis
GO, KEGG, joint classification, and candidate regulatory gene results
Connects site-level changes with biological processes and pathways
Documents project quality and supports next-step decisions
Interpretation note: the site-level signal ratio is intended for relative comparison within the validated project framework. It should not automatically be interpreted as absolute m6A occupancy without an appropriate quantitative strategy.
Applications
Applications Across Animal, Plant, and Microbial Research
m6A-Atlas is best suited to transcriptome-wide, site-level discovery from limited RNA, especially when results must be compared across conditions or integrated with expression.
Gene Regulation and RNA Fate
Study how site-level m6A changes relate to RNA stability, processing, translation, localization, and turnover.
Gene Perturbation and Treatment Response
Compare knockout, knockdown, overexpression, treatment, rescue, or time-course conditions while separating candidate regulatory effects from broad expression responses.
Development and Differentiation
Map dynamic m6A patterns across developmental stages, cell-state transitions, tissue maturation, or differentiation when material is limited.
Disease Mechanism Research
Investigate tumor biology, immunity, metabolism, neurological processes, and host responses through mechanistic research.
Plant Growth and Stress Response
Examine growth, development, drought, temperature stress, pathogen response, and secondary metabolism after review of RNA purity and annotation quality.
Microbial and Virus-Related Research
Explore environmental adaptation, virulence-associated regulation, and host–pathogen interactions, subject to RNA and reference assessment.
Case Study
Case Study: Low-Input m6A Mapping Reveals Neurite-Enriched RNA Methylation
Source
Flamand MN and Meyer KD. m6A and YTHDF proteins contribute to the localization of select neuronal mRNAs. Nucleic Acids Research. 2022;50(8):4464–4483. DOI: 10.1093/nar/gkac251.
Background
Neurons must transport selected mRNAs from the cell body into neurites, but the regulatory signals controlling this localization are not fully understood. The study asked whether m6A contributes to subcellular RNA localization and required a transcriptome-wide method compatible with limited RNA from separated neuronal compartments.
Methods
The researchers used 50 ng total RNA from soma- and neurite-enriched fractions. Candidate sites were evaluated using coverage, matched controls, sequence context, and replicate support, then integrated with RNA abundance, genetic perturbation, reporter assays, and single-molecule imaging.
Results
The analysis identified thousands of high-confidence m6A sites and compartment-associated patterns. The study reported 1,366 RNAs with higher m6A-associated signal in neurites and 136 with higher signal in the soma. Follow-up experiments showed that selected m6A sites contributed to neurite localization.
Conclusion
The study shows how low-input, single-nucleotide-resolution m6A mapping can answer biological questions that broad enrichment profiles alone may not resolve. It also supports combining candidate-site discovery with expression, perturbation, and orthogonal validation.
Figure 4. Original conceptual summary of low-input m6A mapping in neuronal cell bodies and neurites; not reproduced from the publication.
Method Comparison
Choosing the Right m6A Sequencing Strategy
No single m6A method is optimal for every project. Selection depends on available RNA, required resolution, discovery versus validation goals, and whether the project needs relative or absolute measurement.
Best for: limited RNA, transcriptome-wide discovery, single-nucleotide candidate sites, and modification–expression integration across treatments, genotypes, stages, or time points.
Not the best choice when:
Only a few known sites require validation. A targeted method such as SELECT-m6A is more efficient.
Absolute m6A occupancy is required. Relative site signal should not be treated as absolute stoichiometry without a dedicated quantitative strategy.
RNA is severely degraded. Low input cannot compensate for poor molecular integrity.
A broad regional map is sufficient. MeRIP-seq may provide a more established route for enriched-region discovery.
Complete recovery of every m6A site is expected. Site recovery can vary with transcript abundance, sequence context, RNA quality, and sequencing coverage.
